Mainz Biomed announced a strategic partnership with Arztliches Labor Dr. Buhlmann, a move aimed at further strengthening its position in the German market. The collaboration grants Mainz Biomed greater access to, and the potential for further expansion into Germany’s private health insurance segment where ColoAlert, its detection test for colorectal cancer, or CRC, already receives reimbursement.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MYNZ:
- Mainz Biomed Announces Strategic Partnership with Ärztliches Labor Dr. Buhlmann, Expanding Footprint in German Market
- Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
- Mainz Biomed announces commercial launch of ColoAlert in Poland
- Mainz Biomed Announces Live Launch of ColoAlert® with testDNA Laboratory in Poland
- Mainz Biomed price target lowered to $7 from $10 at H.C. Wainwright